<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cover.txt
<TEXT>


               SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C. 20549


                            FORM 8K

                        Current Report
               Pursuant to Section 13 or 15(d) of
              The Securities Exchange Act of 1934



  Date of Report (Date of earliest event reported): July 11,
2006


                        JOHNSON & JOHNSON

     (Exact name of registrant as specified in its charter)


    New Jersey            1-3215              22-1024240

(State or other         Commission        (I.R.S. Employer
jurisdiction           File Number)       Identification No.)
of incorporation)



 One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

      (Address of principal executive offices)   (zip code)


Registrant's telephone number including area code:
                     (732) 524-0400

Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-
2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-
4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Item 8.01.  Other Events.

      On July 6, OrthoNeutrogena, a division of Ortho-McNeil
Pharmaceutical, Inc., a Johnson & Johnson company,  acquired
Colbar  LifeScience  Ltd.,  a privately  held  biotechnology
company  specializing in reconstructive medicine and  tissue
engineering.   Colbar, which is based in  Herzliya,  Israel,
currently  markets  two products that  use  its  proprietary
GlymatrixTM technology:  EvolenceTM, a collagen  for  facial
wrinkles  that  is  sold in Europe,  Canada  and  Japan  and
OssixTM,  a  dental membrane for bone regeneration  that  is
sold  in  the  US and Europe. As a result of the acquisition
Johnson  &  Johnson  expects to incur an estimated  one-time
after-tax charge of approximately $50 million, or  $.02  per
share,  related to the expensing of in-process research  and
development.   Other  terms  of  the  transaction  were  not
disclosed.





                            SIGNATURE



Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.



                                   JOHNSON & JOHNSON




Date: July 11, 2006       By: /s/ Stephen J. Cosgrove
                              Stephen J. Cosgrove
                              Chief Accounting Officer






</TEXT>
</DOCUMENT>